Literature DB >> 34674995

Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives.

L M Camargo1, P C T M Lima2, K Janot3, I L Maldonado4.   

Abstract

In the field of interventional neuroradiology, antiplatelet agents are commonly used to prepare patients before the implantation of permanent endovascular materials. Among the available drugs, clopidogrel is the most frequently used one, but resistance phenomena are considered to be relatively common. Prasugrel and ticagrelor were recently added to the pharmacologic arsenal, but the safety of these agents in patients undergoing neurointerventional procedures is still a subject of discussion. The cumulative experience with both drugs is less extensive than that with clopidogrel, and the experience with patients in the neurology field is less extensive than in the cardiology domain. In the present article, we provide a narrative review of studies that investigated safety issues of oral P2Y12 inhibitors in interventional neuroradiology and discuss potential routes for future research.
© 2021 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34674995      PMCID: PMC8805759          DOI: 10.3174/ajnr.A7303

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  93 in total

1.  Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate.

Authors:  N Flechtenmacher; F Kämmerer; R Dittmer; U Budde; P Michels; J Röther; B Eckert
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-13       Impact factor: 3.825

Review 2.  Personalized approaches to clopidogrel therapy: are we there yet?

Authors:  Christopher D Anderson; Alessandro Biffi; Steven M Greenberg; Jonathan Rosand
Journal:  Stroke       Date:  2010-10-28       Impact factor: 7.914

3.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Authors:  Yongjun Wang; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Chen Wang; Hao Li; Xia Meng; Liying Cui; Jianping Jia; Qiang Dong; Anding Xu; Jinsheng Zeng; Yansheng Li; Zhimin Wang; Haiqin Xia; S Claiborne Johnston
Journal:  N Engl J Med       Date:  2013-06-26       Impact factor: 91.245

4.  Tailored antiplatelet agent medication in clopidogrel hyporesponsive patients before stent-assisted coiling: single-center experience.

Authors:  Ricky Gusanto Kurniawan; Yunsun Song; Boseong Kwon; Yura Ahn; Dae Chul Suh
Journal:  Neuroradiology       Date:  2020-07-13       Impact factor: 2.804

5.  Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: A matched-cohort study comparing clopidogrel with ticagrelor.

Authors:  Sébastien Soize; Cédric Foussier; Pierre-François Manceau; Claude-Fabien Litré; Serge Backchine; Matthias Gawlitza; Laurent Pierot
Journal:  J Neuroradiol       Date:  2019-02-05       Impact factor: 3.447

6.  Clopidogrel hyper-response and bleeding risk in neurointerventional procedures.

Authors:  C Goh; L Churilov; P Mitchell; R Dowling; B Yan
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-28       Impact factor: 3.825

Review 7.  P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

Authors:  Day Marice Scott; Rhonda M Norwood; David Parra
Journal:  Ann Pharmacother       Date:  2008-12-02       Impact factor: 3.154

8.  Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience.

Authors:  D H Lee; A Arat; H Morsi; H Shaltoni; J R Harris; M E Mawad
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-15       Impact factor: 3.825

9.  Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II.

Authors:  Kazuo Kitagawa; Kazunori Toyoda; Takanari Kitazono; Masakatsu Nishikawa; Shinsuke Nanto; Yasuo Ikeda; Kenji Abe; Akira Ogawa
Journal:  Cerebrovasc Dis       Date:  2020-03-24       Impact factor: 2.762

Review 10.  Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

Authors:  Yan-Jiao Zhang; Mu-Peng Li; Jie Tang; Xiao-Ping Chen
Journal:  Int J Environ Res Public Health       Date:  2017-03-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.